A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants
Safety Observation of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in Primary Immunization, Booster Immunization and Simultaneous Vaccination With Other Vaccines in Infants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Jiangxi
-
Gao'an, Jiangxi, China, 330899
- Gaoan Center for Disease Control and Prevention
-
Pingxiang, Jiangxi, China
- Shangli County Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infants aged 2-3 months should be involved in primary immunization and they have not received Sabin strain inactivated polio vaccine (Vero Cell) in the past;
- Children aged 18 months should be immunized with the first three doses of Sabin strain inactivated polio vaccine (Vero Cell) and they have not received any inactivated or attenuated live vaccines in the past 14 days;
- The guardian agrees to sign the informed consent and voluntarily use the mobile APP to participate in the follow-up visits.
Exclusion Criteria:
- Allergic to the active ingredient in the vaccine, any inactive ingredient, or substance used in the manufacturing process;
- Allergic to this product or similar vaccines in the past;
- Patients with severe chronic diseases or allergies;
- Patients with fever or acute illness.
The Exclusion Criteria for the Second and Third Doses:
- Any serious adverse events that are causally related to vaccination;
- Severe anaphylaxis or hypersensitivity after vaccination (including hives and rashes within 30 minutes of vaccination);
- Any confirmed or suspected autoimmune or immunodeficiency disease, including human immunodeficiency virus (HIV) infection;
- Acute or newly emerging chronic diseases occur at the time of vaccination;
- Other reactions (including severe pain, severe swelling, severe limitation of movement, persistent high fever, severe headache, or other systemic or local reactions), as determined by the investigator;
- Having an acute illness at the time of vaccination (acute illness is defined as moderate or severe illness with or without fever);
- Axillary temperature >37℃ during vaccination.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Primary immunization group
A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group
|
All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines.
Subjects recommended intramuscular injection.
The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
|
|
Experimental: Booster immunization group of sIPV vaccine
A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.
|
All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection.
The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine
Time Frame: Within 0~7 days after primary immunization
|
Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine
|
Within 0~7 days after primary immunization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine
Time Frame: Within 0~30 days after primary immunization
|
Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine.
|
Within 0~30 days after primary immunization
|
|
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine
Time Frame: Within 0~7 days after booster immunization
|
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine .
|
Within 0~7 days after booster immunization
|
|
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine
Time Frame: Within 0~30 days after booster immunization
|
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine.
|
Within 0~30 days after booster immunization
|
|
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine
Time Frame: Within 0-7 days after primary immunization combined with DTaP vaccine
|
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine.
|
Within 0-7 days after primary immunization combined with DTaP vaccine
|
|
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine
Time Frame: Within 0-30 days after primary immunization combined with DTaP vaccine
|
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine combined with DTaP vaccine.
|
Within 0-30 days after primary immunization combined with DTaP vaccine
|
|
Incidence of adverse reactions after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine
Time Frame: Within 0~7 days after booster immunization combined with inactivated hepatitis A vaccine
|
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine.
|
Within 0~7 days after booster immunization combined with inactivated hepatitis A vaccine
|
|
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine
Time Frame: Within 0 ~14 days after booster immunization
|
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine combined with MMR vaccine or attenuated hepatitis A vaccine.
|
Within 0 ~14 days after booster immunization
|
|
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine
Time Frame: Within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.
|
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.
|
Within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shicheng Guo, Master, Jiangxi Provincial Center for Disease Prevention and Control
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Neuromuscular Diseases
- Central Nervous System Infections
- Enterovirus Infections
- Picornaviridae Infections
- Spinal Cord Diseases
- Myelitis
- Poliomyelitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
Other Study ID Numbers
- PRO-sIPV-MA4001-JX
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.